Hopp til hovedinnhold
Cystenyrer gir i de fleste tilfeller ingen symptomer i barndom og ungdom. Tilstanden utvikler seg gjerne i 30-50 årsalderen.
Cystenyrer gir i de fleste tilfeller ingen symptomer i barndom og ungdom. Tilstanden utvikler seg gjerne i 30-50 årsalderen.

Cystenyrer

Cystenyrer er en arvelig sykdom. Den medisinske betegnelsen er autosomal dominant polycystisk nyresykdom, forkortet ADPKD.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/nyrerurinveier/andre-nyresykdommer/cystenyrer/ 

Hva er cystenyrer?

Årsak

Hvordan vokser nyrene?

Symptomer

Diagnostikk

Behandling

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Polycystisk nyresykdom. Referanselisten for dette dokumentet vises nedenfor.

  1. Arbejdsgruppe nedsat af Dansk Nefrologisk Selskab. Autosomal dominant polycystisk nyresygdom. Forslag til retningslinjer for patienter og disses slægtninge. Ugeskr Læger 2004; 166: 3807-11. PubMed 
  2. Srivastava A, Patel N. Autosomal dominant polycystic kidney disease. Am Fam Physician. 2014 Sep 1;90(5):303-307. PubMed 
  3. Chapman AB. Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther 2003; 10: 24-30. PubMed 
  4. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-57. PubMed 
  5. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149–168. PMID 19455193
  6. Katre S, Leivestad T, Fauchald P. Aktiv uremibehandling ved autosomal dominant polycystisk nyresykdom. Tidsskr Nor Lægeforen 2000; 120: 1015-9. Tidsskrift for Den norske legeforening 
  7. Demetriou K, Tziakouri C, Anninou Ket al. Autosomal dominant polycystic kidney disease - type 2. Ultrasound, genetic and clinical correlations. Nephrol Dial Transpl 2000; 15: 205-11. PubMed 
  8. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-30. PubMed 
  9. Rosetti S, Burton S, Strmecki L, et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13: 1230. pmid:11961010 PubMed 
  10. Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens. 2012;21(2):189–194.
  11. Perrone RD, Malek AM, Watnick T. Vascular complications in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2015; 11: 589. pmid: 26260542 PubMed 
  12. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–1485.
  13. Kim JA, Blumenfeld JD, Chhabra S, et al. Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations. Radiology 2016; 280: 762. pmid:27046073 PubMed 
  14. Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):173–180.
  15. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–1301.
  16. Bae KT, Sun H, Lee JG, et al. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol 2014; 39: 210-7. pmid:24576800 PubMed 
  17. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017; 377: 1930. pmid:29105594 PubMed 
  18. Wüthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother 2014; 15: 1085-95. doi:10.1517/14656566.2014.903923 DOI 
  19. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
  20. Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis. 2011 Jun. 57(6):856-62.
  21. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT et al. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int 1992; 45: 1311-9. PubMed 
  22. Rozenfeld MN, Ansari SA, Shaibani A, Russell EJ, Mohan P, Hurley MC. Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms? AJNR Am J Neuroradiol. 2014;35(1):3–9.
  23. Bennett WM. Autosomal dominant polycystic kidney disease: 2009 update for internists. Korean J Intern Med. 2009;24(3):165–168.
  24. Sunde L, Schwartz M, et al. Autosomal dominant polycystisk nyresygdom. Ugeskr Læger 2004; 166: 3807-11. Ugeskrift for Læger